RPL32P21

Across TCGA pan-cancer cohorts, RPL32P21 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RPL32P21 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RPL32P21 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL32P21 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LUAD and PDAC are the cancer types where RPL32P21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.446	0.976	.004	21	view →
PDAC	OS	Quartile	All	0.890	0.758	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RPL32P21–LUAD (DFS)

Open the LUAD breakdown →